Huntington disease comes with unanswered questions for the community

An experimental gene therapy shows the ability to slow down the weak progress of Huntington disease, a European Biotech company that has developed a new treatment.

Huntington’s disease is a nervous-destructive disease that goes on in families and damages the movement, loots memory and replaces personality while people are in the head of their lives. It is almost always fatal within 10 to 20 years of diagnosis, says neurologists.

Now, researchers are excited about the results of a company’s small, early clinical studies that targets genetic error caused by a treatment.

Principal Investigator Ed Wild at the Huntington Disease Center, University College London, “I have unbridled optimism, who was involved in an interview with CBC As it happens,

“This is the best news ever in the Huntington community.”

The Netherland -based company, Unicure, announced preliminary findings from an experimental gene therapy on Wednesday, which slowed down the disease progressed by 75 percent in three years for patients with higher doses, suggesting the medical administered therapy during brain surgery. The test was small, in which about 30 patients nominated, and treatment did not treat them the disease.

So what does it mean?

It is a possible promising development for a situation that is some of them since the discovery of the defective genes behind the disease in 1993, but experts say there are still unanswered questions and work further.

Slowing the progression of the disease, while not cure, can improve the quality of life of patients.

Director of University College London Huntington Disease Center, Dr. Sarah Tabariji said, “People will be able to work for a long time, they will be able to work for a long time, they will be able to maintain their freedom,”

But slowing down the progression of the disease can mean those who do not have the right candidates for brain surgery to get potential treatment, this is not clear. This also includes whether people with first or later stages can be eligible for Huntington.

Full data has not been reviewed by public or colleagues by the company independent experts. Those procedures can help identify flaws in experimental design or highlight the best doses or time such as time.

In a media release, the company stated that the results of its top-rich demonstrated “statistically important slow” of the progression of the disease.

Professor of Bioathics at McGill University in Montreal, Dr. Jonathan Kimilman said that in view of the lack of publicly available data, it is difficult to explain and assess the correct impact of the company’s announcement.

“It can be very exciting. It can also be like many other press releases, that is, it can be a very luxurious and selective representation that they have seen.”

Kimmeman also said that the available information shows that the treatment appears to slow down the disease, rather than cure it or prevent it from deteriorating completely.

Others are more optimistic.

Rechhel Harding, an editor in HDBs, a website that focuses on the information about the disease of the Leslie Dan Faculty of Pharmacy at the University of Toronto and an editor in HDBs, said that in the end it is a good feeling to see “something that looks likely in clinical trials.”

However, Harding also recognized the boundaries, such as the size of the small sample of the test-12 patients were followed for 36 months at the highest dosage-and the lack of long-term data.

“Will the effects of the drug or fall or, you know, will it not work and will also increase people’s disease?” Harding said. “We don’t know.”

Surgery and treatment ideas

Brain surgery takes at least 12 hours, said Wilde said, and gene therapy needs to be transported to two areas of the brain during real -time MRI scanning.

The purpose of treatment is to correct the mutant Huntingin genes. Surgeons use a modified virus to provide potential gene therapy treatment, called AMT-130.

Possible treatment aims to a low level of mutant huntingin protein that disrupts the normal function of neurons in the brain. Previous single-khurak gene therapy Cost $ 2 million.

The company said that later this year is a meeting with the US Food and Drug Administration to share data with the agency this year, which is before submitting its 2026 employed to the FDA for marketing approval.